ASH 2021 Conference Coverage on VuMedi

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

ASH 2021 Conference Coverage on VuMedi

Lymphoma
Leukemia
Myeloma
MDS and MPN
Benign Hematology
COVID-19 and Blood Cancers

Playback speed

10 seconds

ASH 2021: Glofitamab + R-CHOP Induces High Response Rates With Minimal CRS in R/R NHL and 1L DLBCL

By ASH 2021 Conference Coverage on VuMedi FEATURING Nilanjan Ghosh

157 views

December 20, 2021

Comments 0

Making the First Chance Count: Manuel

Feat. A. Ip

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

Lymphoma

A Multi-Institution Analysis of Relapsed Lymphoma Occurring During P…

ASH 2021 Conference Coverage on VuMedi

F. Farooq

15 views

ASH 2021 Five-Year Follow-Up of Keynote-087: Pembrolizumab Monothera…

ASH 2021 Conference Coverage on VuMedi

A. Herrera

281 views

ASH 2021 Highlights: CAR-T as 2L Therapy in R/R Aggressive NHL

ASH 2021 Conference Coverage on VuMedi

N. Ahmed

91 views

ASH 2021 Update on the Safety and Efficacy of CD37-Targeting Naratux…

ASH 2021 Conference Coverage on VuMedi

M. Y. Levy

121 views

ASH 2021 Update on the Outcomes & Treatment Patterns in Pts With Agg…

ASH 2021 Conference Coverage on VuMedi

J. Zurko

221 views

ASH 2021 Update on a Phase II Study of OB-VEN in Patients With HTB-F…

ASH 2021 Conference Coverage on VuMedi

C. Portell

76 views

ASH 2021 Updates on Managing R/R DLBCL: Surveying Treatment Landscape

ASH 2021 Conference Coverage on VuMedi

A. Goy

24 views

ASH 2021 Update on Brexucabtagene Autoleucel for R/R MCL: Real-World…

ASH 2021 Conference Coverage on VuMedi

Y. Wang

23 views

ASH 2021 Highlights on Concurrent Pembrolizumab With AVD for Untreat…

ASH 2021 Conference Coverage on VuMedi

R. C. Lynch

82 views

ASH 2021 Updates on Allogeneic CAR-T PBCAR0191 With Intensified Lymp…

ASH 2021 Conference Coverage on VuMedi

B. Shah

66 views

ASH 2021: Glofitamab + R-CHOP Induces High Response Rates With Minim…

ASH 2021 Conference Coverage on VuMedi

N. Ghosh

157 views

ASH 2021 Frontline Treatment With Pembrolizumab Followed by AVD Chem…

ASH 2021 Conference Coverage on VuMedi

P. Allen

243 views

ASH 2021 Updates on the Umbralisib + Ublituximab Combo in R/R MZL: R…

ASH 2021 Conference Coverage on VuMedi

J. Chavez

63 views

ASH 2021 Highlights on Real-World Case Studies in ctDNA

ASH 2021 Conference Coverage on VuMedi

P. Blombery

81 views

ASH 2021 Updates on CD30-Directed CAR T-Cells for Pediatric Patients…

ASH 2021 Conference Coverage on VuMedi

G. Hucks

43 views